Page last updated: 2024-08-24

cilazapril, anhydrous and Primary Peritonitis

cilazapril, anhydrous has been researched along with Primary Peritonitis in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Ding, JL; Hao, JB; Hao, LR; Ren, LS; Zhang, L	1

Other Studies

1 other study(ies) available for cilazapril, anhydrous and Primary Peritonitis

Article	Year
The aldosterone receptor antagonist spironolactone prevents peritoneal inflammation and fibrosis. Laboratory investigation; a journal of technical methods and pathology, 2014, Volume: 94, Issue:8 Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Anti-Inflammatory Agents; Cilazapril; Dialysis Solutions; Disease Models, Animal; Drug Therapy, Combination; Lymphocytes; Macrophages; Male; Mineralocorticoid Receptor Antagonists; Peritoneal Dialysis, Continuous Ambulatory; Peritoneal Fibrosis; Peritoneum; Peritonitis; Random Allocation; Rats; Rats, Wistar; Receptors, Mineralocorticoid; Spironolactone; Transforming Growth Factor beta1	2014

Article

Year

The aldosterone receptor antagonist spironolactone prevents peritoneal inflammation and fibrosis.

Laboratory investigation; a journal of technical methods and pathology, 2014, Volume: 94, Issue:8

Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Anti-Inflammatory Agents; Cilazapril; Dialysis Solutions; Disease Models, Animal; Drug Therapy, Combination; Lymphocytes; Macrophages; Male; Mineralocorticoid Receptor Antagonists; Peritoneal Dialysis, Continuous Ambulatory; Peritoneal Fibrosis; Peritoneum; Peritonitis; Random Allocation; Rats; Rats, Wistar; Receptors, Mineralocorticoid; Spironolactone; Transforming Growth Factor beta1

2014